TL;DR
This paper introduces DeepTRIAGE, a novel deep learning architecture that not only classifies breast cancer subtypes with high accuracy but also provides individualized biomarker scores for each patient. This allows for a deeper understanding of patient-specific feature importance and reveals previously hidden heterogeneity within cancer subtypes, potentially leading to new diagnostic and therapeutic hypotheses.
What Problem Does This Paper Address?
Breast cancer is a complex disease with various molecular subtypes, each having distinct prognoses and treatment responses. Accurately classifying these subtypes is crucial for clinical decision-making. While machine learning has been applied to gene expression data for this purpose, existing methods often struggle with the high dimensionality of the data (more features than samples) and provide only class-level feature importance, failing to capture the significant heterogeneity that exists within established subtypes. This lack of individual-level interpretability limits our ability to understand patient-specific disease mechanisms and discover new biological insights.
Methods
The core of this work is the DeepTRIAGE architecture, a deep learning model that leverages an attention mechanism to address the challenges of high-dimensional gene expression data.
- Attention Mechanism: Inspired by its success in natural language processing and computer vision, the authors adapt an attention mechanism to gene expression data. This allows the model to dynamically focus on the most salient features for classifying each individual patient.
- Individualized Biomarker Scores: Crucially, DeepTRIAGE generates personalized "biomarker scores" for each patient. These scores quantify the importance of each feature (gene or gene set) in classifying that specific patient, moving beyond generic, class-level importance.
- Feature Engineering: To manage the high dimensionality, the authors transform raw gene expression data into an "annotation space" using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. This aggregates gene-level information into pathway-level features.
- Model Architecture: DeepTRIAGE uses an embedding layer to reduce feature dimensionality, followed by an attention mechanism to compute sample-specific feature weights, and finally a classifier to predict the subtype. The entire model is trained end-to-end using an Adam optimizer.
Datasets
The study utilizes publicly available gene-level RNA-Seq data for the TCGA breast cancer (BRCA) cohort. Subtype information (luminal A and luminal B) was obtained from the "PAM50" labels. The dataset was split into training and testing sets, with 528 luminal A and 201 luminal B samples for training, and 176 luminal A and 67 luminal B samples for testing.
Key Insights and Ideas
- Interpretability at the Individual Level: The most significant contribution is the ability to generate patient-specific feature importance scores. This moves beyond simply classifying a sample and allows for a deeper, personalized understanding of the molecular drivers of disease in each individual.
- Uncovering Latent Heterogeneity: By analyzing the individualized biomarker scores, the authors demonstrate that DeepTRIAGE can reveal subtle variations and subgroups within established cancer subtypes (e.g., luminal A) that are not apparent with traditional methods.
- Bridging Biology and Data: The use of GO and KEGG annotations as features, combined with the interpretable scores, helps connect the data-driven insights back to biological pathways and functions, facilitating hypothesis generation for further research.
- Attention for High-Dimensional Genomics: The paper showcases the successful adaptation of attention mechanisms to handle the "p >> n" problem common in genomics, where the number of features far exceeds the number of samples.
Key Results
- Competitive Classification Accuracy: DeepTRIAGE achieves comparable, and in some cases slightly better, classification accuracy for luminal A vs. luminal B subtypes compared to traditional methods like Logistic Regression and Linear SVM, using both gene and gene set features.
- Identification of Key Biomarkers:
- Using gene expression data, the gene GINS1 was identified as a highly important feature for distinguishing subtypes.
- Using GO annotations, the kinetochore organization gene set (GO:0051383) was found to be a strong discriminator between luminal A and B subtypes.
- Association with Tumor Severity: Analysis of the individualized biomarker scores revealed that within the luminal A subtype, variations in these scores significantly associated with tumor stage (T, N, M), suggesting that DeepTRIAGE can place luminal samples along a continuum of severity. This aligns with the understanding that luminal B cancers are generally more severe.
Limitations and Future Work
- Focus on Luminal Subtypes: The current study focuses specifically on the luminal A and luminal B subtypes. Future work could extend DeepTRIAGE to classify all major breast cancer subtypes.
- Model Complexity: While the attention mechanism is adapted for high dimensionality, the authors acknowledge that more complex functions could be chosen for the feed-forward networks within the architecture.
- Hypothesis Generation: The paper presents DeepTRIAGE as a tool for generating new hypotheses. Further experimental validation of these hypotheses would be a natural next step.
- Broader Applications: The authors suggest that DeepTRIAGE is a general solution for classification and stratification of biological samples using gene expression data, implying its potential applicability to other diseases and data types.
Summary updated